Clinical Trials Browser

Phase 2/3 × INDUSTRY × Immunotherapy × Clear all

NCT06624644 2025-09-10

A Trial of LNS8801 With or Without Pembrolizumab in Patients With Refractory Melanoma

Phase 2/3 Recruiting

Melanoma